Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9780MR)

This product GTTS-WQ9780MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9780MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ979MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ3353MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ15890MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ1755MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ15868MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ3776MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ9855MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ10688MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LymphoStat-B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW